| Patent application number | Description | Published |
|---|
| 20090095165 | Machine for brewing a beverage such as coffee and related method - A machine for brewing a beverage such as coffee includes a chamber and a piston disposed in the chamber. The piston is operable to move to a first position to allow the chamber to receive a liquid and a flavor base such as ground coffee, to remain in the first position for a time sufficient for the beverage to brew, and to move to a second position to dispense the beverage by forcing the beverage out of the chamber. By modifying some or all steps of the French press brewing technique, the machine can typically control coffee-brewing parameters with a level of precision that yields brewed coffee having a uniform taste from cup to cup, and can typically brew the coffee with a speed that renders the machine suitable for use by establishments that serve significant amounts of coffee. | 04-16-2009 |
| 20100024657 | Machine for brewing a beverage such as coffee and related method - A machine for brewing a beverage such as coffee includes a chamber and a piston disposed in the chamber. The piston is operable to move to a first position to allow the chamber to receive a liquid and a flavor base such as ground coffee, to remain in the first position for a time sufficient for the beverage to brew, and to move to a second position to dispense the beverage by forcing the beverage out of the chamber. By modifying some or all steps of the French press brewing technique, the machine can typically control coffee-brewing parameters with a level of precision that yields brewed coffee having a uniform taste from cup to cup, and can typically brew the coffee with a speed that renders the machine suitable for use by establishments that serve significant amounts of coffee. | 02-04-2010 |
| 20110088560 | Machine for Brewing a Beverage Such as Coffee and Related Method - A machine for brewing a beverage such as coffee includes a chamber and a piston disposed in the chamber. The piston is operable to move to a first position to allow the chamber to receive a liquid and a flavor base such as ground coffee, to remain in the first position for a time sufficient for the beverage to brew, and to move to a second position to dispense the beverage by forcing the beverage out of the chamber. By modifying some or all steps of the French press brewing technique, the machine can typically control coffee-brewing parameters with a level of precision that yields brewed coffee having a uniform taste from cup to cup, and can typically brew the coffee with a speed that renders the machine suitable for use by establishments that serve significant amounts of coffee. | 04-21-2011 |
| Patent application number | Description | Published |
|---|
| 20090041765 | Materials and methods for improved immunoglycoproteins - Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins. | 02-12-2009 |
| 20090142801 | BTL-II NUCLEIC ACIDS - The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen. | 06-04-2009 |
| 20090258005 | Therapeutic compositions and methods - The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2. | 10-15-2009 |
| 20090304590 | Therapeutic compositions and methods - The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2. | 12-10-2009 |
| 20100168399 | ANTIBODIES THAT BIND B7L-1 - The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides. | 07-01-2010 |
| 20100330104 | METHODS OF USING BTL-II PROTEINS - The invention provides isolated BTL-II proteins, nucleic acids, antibodies, antagonists, and agonists and methods of making and using the same. Diagnostic, screening, and therapeutic methods using the compositions of the invention are provided. For example, the compositions of the invention can be used for diagnosis and treatment of inflammatory bowel diseases and for enhancing a mucosal immune response to an antigen. | 12-30-2010 |
| Patent application number | Description | Published |
|---|
| 20080227958 | BINDING PROTEINS COMPRISING IMMUNOGLOBULIN HINGE AND FC REGIONS HAVING ALTERED FC EFFECTOR FUNCTIONS - Provided herein are binding proteins comprising one or more immunoglobulin Fc region hinge, CH2, and/or CH3 domain wherein one or more hinge and/or constant region CH2 and/or CH3 domain is modified to alter the binding protein's binding affinity and/or specificity for a cognate receptor (e.g., an Fc receptor) and/or to impart one or more new binding specificity(ies) to the hinge and/or constant region that the corresponding unmodified immunoglobulin does not possess (e.g., affinity for distinct class of cognate receptor distinct from the class of cognate receptor to which the unmodified binding protein specifically binds). Binding proteins according to the present invention include, for example, modified antibodies, antibody fragments, recombinant binding proteins, and molecularly engineered binding domain-immunoglobulin fusion proteins, including small modular immunopharmaceutical products (SMIP™ products). | 09-18-2008 |
| 20090011499 | Antibodies that bind LDCAM - The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides. | 01-08-2009 |
| 20090155845 | Molecules designated LDCAM - The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides. | 06-18-2009 |
| 20100144640 | MOLECULES DESIGNATED B7L-1 - The invention is directed to B7L-1 as a purified and isolated protein, the DNA encoding the B7L-1, host cells transfected with cDNAs encoding B7L-1 and processes for preparing B7L-1 polypeptides. | 06-10-2010 |
| 20100150948 | MATERIALS AND METHODS FOR IMPROVED IMMUNOGLYCOPROTEINS - Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immuno-glycoproteins. | 06-17-2010 |
| 20100215572 | METHODS OF TREATMENT USING LDCAM - The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides. | 08-26-2010 |
| 20100279350 | C-type lectin polypeptide, polynucleotide and methods of making and use thereof - Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides. | 11-04-2010 |
| 20110142851 | IL6 Immunotherapeutics - A binding domain polypeptide and fusion proteins thereof that recognize an IL6/IL6 receptor complex, as well as compositions and methods of use thereof. | 06-16-2011 |
| 20110152173 | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS - This disclosure provides a multi-target fusion protein composed of a TNF-α antagonist domain and another binding domain antagonistic for a heterologous target, such as IL6, RANKL, IL7, IL17A/F, TWEAK, CSF2, IGF1, IGF2 or BLyS/APRIL, or agonistic for a heterologous target, such as IL10. The multi-specific fusion protein may also include an intervening domain that separates the binding domains and allows for dimerization. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions. | 06-23-2011 |
| 20110158995 | Multi-Specific Binding Proteins Targeting B Cell Disorders - This disclosure provides a multi-specific fusion protein composed of a CD72-ligand binding domain and another binding domain specific for a heterologous target, such as a B-cell specific protein. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions. | 06-30-2011 |
